Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
April 6th is the start of new tax year and new £20k ISA allowance, given the direction we know the company is heading it's a good chance to secure the shares/divis in a tax free wrapper using the 2021/22 isa allowance starting on April 6th
Ah trades now showing @ 15.25! Recommend bed and isa for anyone who hasn't used thier allowance this year
Thanks for this Si, I followed suit and did the bed and isa earlier with Barclays, got a text confirmation after 5 mins or so and my 46k OO shares are now safely stashed away in an ISA, they sold for 30p and bought back for 30.06p so not bad at all. Can't see the trades in the lse list so presume they're listed on a different exchange. The whole process was seamless. Small fry holding compared to many but I've been averaging up all the way since Jan 2020 and never thought future CGT would be an issue, nice issue to have of course and testament to this brilliant company that continues to grow. Looking forward to topping up further moving into the 2021/22 tax year. Also good to know future dividends will now also be protected from tax. GL all!
Fantastic news, this also now unlocks other covid 19 challenge study contracts with worldwide big pharma company's. Won't be long before CF announces a 4th facility in the UK and then looks at licencing the studies abroad as the world leader in the testing of vaccines and anti virals through human challenge studies!
Great question. I was attracted to Open Orphan in Janaury 2020 after the acquisition of Hvivo, I could see the Hvivo valuation looked too low. I knew Imutex and flu V was included from remembering Hvivo souring a couple years earlier after the positive phase 2 results and could see Hvivo had been sold down due to Woodford who owned c29%. So my first thoughts were it looked like Orphan Orphan had picked Hvivo up at a cut price deal, despite being loss making at the time. Then, 2 months later the pandemic set it. I wanted some exposure to Covid opportunities but more of a lower risk 'picks and shovels' option and once realising Hvivo was the 'world leader in the testing of vaccines" I thought the game has changed here, Covid is not going away and suddenly Vaccine development and testing be it covid or non covid is going to be vitally important in the years ahead.
My decision to first invest was wholly fundementally based. The major lesson I have learnt is that management is everything in an investment. Knowing that Cathal had invested half of his personal wealth in the company was a huge vote of confidence, the 3 year lock in period, modest salaries and focus on streamlining costs and making the company profitable from the outset were of massive importance. Then you have Venn, monetising the non core assets and data, suddenly I thought this is not a trade for 20/30%, this is an accumulate and hold company. I've continued to accumulate by averaging up since Jan 2020 and will continue to hold until the company is sold at many multiples of the current valuation.
Having been burnt in many high risk jam tomorrow company's with huge discounted placings and poor management, this really is a gem of a company. Given what has been achieved so far, I have no doubt Cathal can take it to a $1bn market cap, given the sector and opportunities ahead.
I have similar query, am holding my Open Orphan through Barclays who don't offer overseas share trading. If the non core assets are spun off into a Nasdaq vehicle and we receive a shareholding in the new Nasdaq vehicle would Barclays send me a share certificate to then access this new holding via setting up an account with a different broker? Just wondering if I should be looking to transfer brokers now beforehand? Any advice appreciated. Cathal and his team are doing a fantastic job!
Icon listed on Nasdaq could be an interested acquirer as ORPH would be a good fit for them. It has been mentioned on here before. $10bn market cap so would easily swallow us up. Still think there could be something in the SGS link possibly by end of 2021?
He's on at 18:55, looking forward to it. Happy to continue accumulating while the story plays out, Cathal's comments in latest rns moving into 2021 say it all!
Looking forward to Cathal's presentation on Thursday, I'm sure he give his thoughts on the Biondvax news and how this can position Imutex going forward, leaves Flu-V as a real front runner for a universal flu vaccine
I remember Cathal mention a while back that a Flu-V peptide could be swapped out for a Covid19 peptide? Anyone think we could get an update on whether Imutex could possibly be a viable Covid 19 vaccine candidate if this process works and could be tested? Just wondered if this could happen before a sale of Imutex. Seems to be aggressive buying again today with large volume
Interesting, they're a $10bn market cap company , would be small change for them but equally I'd be more than happy to let CF continue to grow the company and then worry about big premium t/over offers much further down the line
Great summary and really highlights the growth opportunity in what is undoubtedly a company very well placed in the hot sector of pharma services/vaccine testing. CF has said he expects this area to be of high interest for the next decade when pre covid nobody wanted to know, clearly the landscape has changed now. Out of interest, if a big pharma did come knocking in the months/years ahead are there any specific names that would see Open Orphan as a natural fit or a pharma vaccine development company that would want to snap up the lucatrative offering that OO provides. Any UK or US listed names that spring to mind?
It now looks only a matter of time before confirmation of UK covid human challenge studies and the spotlight will be on OO/Hvivo in playing a massive role in covid vaccine testing. The way Cathal has guided the market with gradual upward momentum is superb and for me the best part is knowing Cathal has half his net wealth invested locked up for another 2 years fully aligned with all shareholders. Happy to keep topping up and letting the best Chairman/CEO on AIM continue to deliver
This will be all over the global news stations, Cathal delivers yet again. What an investment this is proving to be with so many Covid and Non -Covid revenue streams. Not to mention the wearables database to be licensed and the non core Imutex and PrepBiopharm stakes to be monetised!
I guess we'll get a full update on the Imutex positon/discussions as part of the interims? The £12m was purely raised to put the company in a robust cash position to add confidence to the big pharma coy's signing up for the covid challenge studys. We're now cash generative and it will continue to scale up. No question where this company is heading
Once again, another excellent presentation from Cathal, think you'd be hard pushed to find a better all rounder in any other AIM company . So many irons in the fire excited to see how it all plays out with massive room for growth and SP acceleration.
Evening all, with the many irons in the fire , right place right time sector and diversification that the company provides, will Cathal still look to sell the company end of 2020 early 2021 or continue to scale up and build over a longer term? Obviously a sale / listing of Imutex is on the cards but what about reaminder of OO?
They always say management is everything in Aim company's. Having watched all the investor presentations , really think you'd be hard pressed to find a better Exec Chairman on Aim than Cathal especially one with a £2.5m investment locked up for 3 years being fully aligned with PI's.
Exciting second half of the year in store!